TRIB Stock Overview
Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Trinity Biotech plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.88 |
| 52 Week High | US$6.20 |
| 52 Week Low | US$1.79 |
| Beta | 1.23 |
| 1 Month Change | -14.16% |
| 3 Month Change | -13.56% |
| 1 Year Change | -67.02% |
| 3 Year Change | -89.61% |
| 5 Year Change | -86.43% |
| Change since IPO | -97.65% |
Recent News & Updates
Recent updates
Investors Don't See Light At End Of Trinity Biotech plc's (NASDAQ:TRIB) Tunnel And Push Stock Down 27%
Mar 02
Trinity Biotech plc's (NASDAQ:TRIB) Shares Bounce 31% But Its Business Still Trails The Industry
Dec 18A Look At The Fair Value Of Trinity Biotech plc (NASDAQ:TRIB)
Sep 12Should You Investigate Trinity Biotech plc (NASDAQ:TRIB) At US$0.80?
Aug 08Insufficient Growth At Trinity Biotech plc (NASDAQ:TRIB) Hampers Share Price
Jun 09Calculating The Intrinsic Value Of Trinity Biotech plc (NASDAQ:TRIB)
Apr 23This Broker Just Slashed Their Trinity Biotech plc (NASDAQ:TRIB) Earnings Forecasts
Apr 23Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?
Mar 01Trinity Biotech appoints former GE executive Aris Kekedjian as CEO
Oct 03At US$1.22, Is Trinity Biotech plc (NASDAQ:TRIB) Worth Looking At Closely?
Sep 01Trinity Biotech GAAP EPADS of -50c, revenue of $18.78M misses by $1.22M
Jun 30Returns Are Gaining Momentum At Trinity Biotech (NASDAQ:TRIB)
Jun 14Does Trinity Biotech (NASDAQ:TRIB) Have A Healthy Balance Sheet?
Mar 23Is Trinity Biotech plc (NASDAQ:TRIB) Popular Amongst Insiders?
Feb 25Trinity Biotech plc (NASDAQ:TRIB) Could Be Less Than A Year Away From Profitability
Feb 02
A Treatise On Trinity Biotech
Jan 13Did You Miss Trinity Biotech's (NASDAQ:TRIB) Impressive 241% Share Price Gain?
Jan 05What Do The Returns At Trinity Biotech (NASDAQ:TRIB) Mean Going Forward?
Dec 10Trinity Biotech (NASDAQ:TRIB) Takes On Some Risk With Its Use Of Debt
Nov 19Trinity Biotech EPS beats by $0.22, beats on revenue
Nov 17Shareholder Returns
| TRIB | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.7% | -4.1% | -3.7% |
| 1Y | -67.0% | -2.2% | 20.5% |
Return vs Industry: TRIB underperformed the US Medical Equipment industry which returned -2.2% over the past year.
Return vs Market: TRIB underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| TRIB volatility | |
|---|---|
| TRIB Average Weekly Movement | 13.0% |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRIB's share price has been volatile over the past 3 months.
Volatility Over Time: TRIB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 398 | John Gillard | www.trinitybiotech.com |
Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren’s syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.
Trinity Biotech plc Fundamentals Summary
| TRIB fundamental statistics | |
|---|---|
| Market cap | US$17.75m |
| Earnings (TTM) | -US$36.87m |
| Revenue (TTM) | US$56.83m |
0.3x
P/S Ratio-0.5x
P/E RatioIs TRIB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRIB income statement (TTM) | |
|---|---|
| Revenue | US$56.83m |
| Cost of Revenue | US$37.38m |
| Gross Profit | US$19.45m |
| Other Expenses | US$56.32m |
| Earnings | -US$36.87m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.90 |
| Gross Margin | 34.22% |
| Net Profit Margin | -64.87% |
| Debt/Equity Ratio | -229.1% |
How did TRIB perform over the long term?
See historical performance and comparison